| Literature DB >> 35844097 |
Xinyi Huang1, Yu Han2, Shuangyan Yang.
Abstract
Objective: This study aimed to systematically analyze the effect and stability of miniscrew-assisted rapid palatal expansion (MARPE) to provide a reference for the clinical treatment of patients with maxillary transverse deficiency (MTD).Entities:
Keywords: Expansion; Orthodontic mini-implant; Tooth movement
Year: 2022 PMID: 35844097 PMCID: PMC9512629 DOI: 10.4041/kjod21.324
Source DB: PubMed Journal: Korean J Orthod Impact factor: 1.361
Figure 1Flow diagram showing the study selection.
Variable definition
| Variable | Definition |
|---|---|
| Intermolar width | Linear distance between right and left maxillary first molars |
| Alveolar width | Linear distance between right and left maxillary first molar alveolar bone |
| Suture expansion at ANS | Transverse width between anterior nasal spine points |
| Suture expansion at PNS | Transverse width between posterior nasal spine points |
| Tooth inclination | Angle between the long axis of the maxillary first molar and the palatal plane |
| Alveolar height | Distance from the most inferior alveolar point at mesiobucccal root of maxillary first molar to |
Baseline: Line passing through the lowest point at the inferior inner contour of the nasal cavity on the same side, parallel to the axial plane.
Characteristics of included studies
| Author | Year | Design | Group | Size | Sex (male/female) | Average age (yr) | Appliance | Activation protocol | Retention time | Measurement methods | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lagravère et al.[ | 2010 | >RCT | >MARPE | 21 | >8/13 | 14.24 ± 1.32 | >Bone-borne | >0.25 mm/d | >6 months | >CBCT | >6 months, 1 year |
| >RPE | 20 | >5/15 | 14.05 ± 1.35 | >Hyrax expander | >0.5 mm/d | >6 months | |||||
| >Control | 21 | >6/15 | 12.86 ± 1.19 | — | — | — | |||||
| Lin et al.[ | 2015 | >NRCT | >MARPE | 15 | >0/15 | 18.1 ± 4.4 | >C-expander | >0.25 mm/d | — | >CBCT | >3 months |
| >RPE | 13 | >0/13 | 17.4 ± 3.4 | >Hyrax expander | |||||||
| Yılmaz et al.[ | 2015 | >NRCT | >MARME | 14 | >8/6 | 13.2 ± 2.1 | >Bone-borne expander | 0.4 mm/d for first 7–10 d, 0.2 mm/3 d after the opening of the suture | — | Cephalograms, posteroanterior radiographs, dental casts | — |
| >Bonded RME | 14 | >8/6 | 12.1 ± 2.1 | >Bonded expander | |||||||
| >Banded RME | 14 | >6/8 | 13.4 ± 1.7 | >Banded expander | |||||||
| Akin et al.[ | 2016 | >NRCT | >MARPE | 9 | >5/4 | 13.61 ± 0.72 | >Hybrid expander | 0.5 mm/d for the first week, then 0.25 mm/d for 3 weeks | — | >CBCT | — |
| Choi et al.[ | 2016 | >NRCT | >MARPE | 20 | >10/10 | 20.9 ± 2.9 | >Bone-borne expander | >0.2 mm/2 d | >3 months | Posteroanterior cephalograms | >30.2 ± 13.2 months |
| Cantarella et al.[ | 2017 | >NRCT | >MARPE | 15 | >6/9 | 17.2 ± 4.2 | Maxillary skeletal expander | 0.5 mm/d at first, then 0.25 mm/d after inter-incisal diastema appeared | >More than 3 months | >CBCT | — |
| Lim et al.[ | 2017 | >NRCT | >MARPE | 24 | >8/16 | 21.6 ± 3.1 | >Bone-borne expander | >0.2 mm/d | >4 months | >CBCT | 1 year (14.17 ± 2.70 month) |
| Park et al.[ | 2017 | >NRCT | >MARPE | 14 | >9/5 | 20.1 ± 2.4 | >Bone-borne expander | >0.2 mm/d | — | >CBCT | — |
| Celenk-Koca et al.[ | 2018 | >RCT | >Conventional- | 20 | >8/12 | 13.84 ± 1.36 | >Hyrax expander | >2 turns/d | — | >CBCT | — |
| >MARPE | 20 | >7/13 | 13.81 ± 1.23 | Miniscrew-support expander | |||||||
| Ngan et al.[ | 2018 | >NRCT | >MARPE | 8 | >6/2 | 21.9 ± 1.5 | Maxillary skeletal expander | Varied with the severity of transverse discrepancy | — | >CBCT | — |
| Oliveira et al.[ | 2020 | >NRCT | >MARPE | 28 | >10/18 | 15–37 | Miniscrew-support expander | >2/4 turn/d | >4 months | >CBCT | >6 months |
| Jia et al.[ | 2021 | >RCT | >MARPE | 30 | >9/21 | 14.8 ± 1.5 | >Hyrax expander | >0.5 mm/d | >3 months | >CBCT | — |
| >Hyrax | 30 | >12/18 | 15.1 ± 1.6 | Four-point MARPE expander |
RCT, randomized controlled trial; NRCT, non-randomized controlled trial; MARPE, miniscrew-assisted rapid palatal expansion; RPE, rapid palatal expansion; RME, rapid maxillary expansion; CBCT, cone beam computed tomography.
Risk of bias for randomized controlled trials based on Cochrane’s risk of bias tool
| Author | Year | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other sources of bias | Overall bias |
|---|---|---|---|---|---|---|---|---|---|
| Lagravère et al.[ | 2010 | Low risk | Unclear | Low risk | Unclear | Low risk | Unclear | Low risk | Low risk |
| Celenk-Koca | 2018 | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear | Low risk | Low risk |
| Jia et al.[ | 2021 | Low risk | Low risk | Low risk | Unclear | Low risk | Unclear | Low risk | Low risk |
Methodological index for non-randomized controlled trials based on MINORS
| Author | Year | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lin et al.[ | 2015 | 2 | 1 | 2 | 2 | 1 | 1 | 2 | 0 | 2 | 1 | 1 | 2 | 17 |
| Yılmaz et al.[ | 2015 | 2 | 1 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 21 |
| Akin et al.[ | 2016 | 2 | 1 | 2 | 2 | 0 | 0 | 2 | 0 | 9 | ||||
| Choi et al.[ | 2016 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 12 | ||||
| Cantarella et al.[ | 2017 | 2 | 2 | 2 | 2 | 0 | 0 | 2 | 0 | 10 | ||||
| Lim et al.[ | 2017 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 14 | ||||
| Park et al.[ | 2017 | 2 | 2 | 2 | 2 | 0 | 0 | 2 | 0 | 10 | ||||
| Ngan et al.[ | 2018 | 2 | 2 | 2 | 2 | 0 | 0 | 2 | 0 | 10 | ||||
| Oliveira et al.[ | 2020 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 14 |
Items 1–12 represent the following: (1) a clearly stated aim; (2) inclusion criteria for consecutive patients; (3) prospective collection of data; (4) endpoints appropriate for the aim of this study; (5) unbiased assessment of the study endpoint; (6) follow-up period appropriate to the aim of the study; (7) loss to follow-up of less than 5%; (8) prospective calculation of study size; (9) adequate control group; (10) contemporary group; (11) baseline equivalence of groups; and (12) appropriate statistical analyses. A score of 0 means not mentioned, 1 means reported but inadequate, and 2 means reported and adequate. The total score is 24 for studies with control groups and 16 for studies without control groups. Quality is considered low (0–9 for studies with control groups, 0–7 for studies without control groups), moderate (10–20 for studies with control groups, 8–13 for studies without control groups), or high (20–24 for studies with control groups, 14–16 for studies without control groups) based on the total score.
MINORS, methodological index for non-randomized studies.
Figure 2Forest plot of the effects and stability of miniscrew-assisted rapid palatal expansion (MARPE). The outcomes assessed are: (A) intermolar width before and after MARPE; (B) alveolar width before and after MARPE; (C) intermolar width immediately after and 1 year after MARPE; (D) alveolar width immediately after and 1 year after MARPE; (E) tooth inclination of the right and left maxillary first molars after MARPE; and (F) buccal alveolar height of the right and left maxillary first molars before and after MARPE.
CI, confidence interval; IV, inverse variance; SD, standard deviation.